Oral Hormone Therapy Linked to Higher Stroke Risk
A study published September 23, 2026, found oral estrogen linked to increased risks for stroke and blood clots.
Updated on Oct. 9, 2026 in Stroke
Live Poll
Does this study make you less confident in the safety of your current hormone therapy?
Research published in The BMJ on September 23, 2026, identified a link between oral menopausal hormone therapy and elevated risks of venous thromboembolism, ischemic stroke, and myocardial infarction. The nested case-control study analyzed data from thousands of women aged 50 to 69 to compare hormone therapy outcomes against non-users.
Why it matters
These findings provide critical evidence for patients and clinicians evaluating the safety of menopausal treatments. The data highlights a distinct safety profile difference between oral hormone therapy and transdermal alternatives regarding thrombotic risks.
Researchers found oral estrogen use associated with a 1.6 hazard ratio for venous thromboembolism, while oral estradiol doses exceeding 1 mg daily were linked to higher risks of stroke and heart attack.
The players
The BMJ
The BMJ is a peer-reviewed medical journal that publishes original research and clinical reviews covering a wide range of global health topics.
The details
The study included 9,807 women with venous thromboembolism, 18,460 with ischemic stroke, and 11,974 with myocardial infarction, compared against large matched control groups. While oral therapy showed increased hazards, transdermal therapy appeared largely safe, with the exception of myocardial infarction risk in users of combined cyclic therapy.
Timeline
September 23, 2026: The study was published online in The BMJ.
October 8, 2026: The findings were covered in an article by HealthDay.
The Big Picture
This research follows a pattern set by the Women's Health Initiative hormone therapy trials, which established the foundational risks of hormone replacement, by further refining the safety profile based on specific administration methods.
Patients currently using oral estrogen at doses above 1 mg daily should discuss these findings with their healthcare provider to assess potential risk factors. The study suggests that transdermal options may offer a safer profile for certain women, though medical consultation is essential.
The takeaway
Patients should discuss the delivery method of their hormone therapy with a doctor, as oral and transdermal routes present different safety profiles. This study underscores the importance of personalized care when balancing the benefits of hormone replacement against cardiovascular risks.
Further reading
For more information on current treatment safety, visit the Stroke section.
Live Poll
Does this study make you less confident in the safety of your current hormone therapy?
